AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9665078 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI)
Number of subjects: 17
Study 9665078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8080233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg single dose
Number of subjects: 1402
Study 8080233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study 2635255 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 120 mg
Number of subjects: 9
Study 2635255 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 9
Study 2635255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31889382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 30
Study 31889382 — intervention group
Group type: COMPARATOR
Intervention: IPL
Number of subjects: 30
Study 31113728 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT ≤0.80
Number of subjects: 68
Study 31113728 — intervention group
Group type: COMPARATOR
Intervention: FFRCT >0.80
Number of subjects: 68
Study 29191585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel (10mg/kg and 75mg/m2 respectively)
Number of subjects: 1253
Study 29191585 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1253
Study 29191585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1253
Study 26110437 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich beverage
Number of subjects: 28
Study 26110437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22910100 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-exposed group
Number of subjects: 16
Study 22910100 — intervention group
Group type: COMPARATOR
Intervention: Dark-exposed group
Number of subjects: 16
Study 22436478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0
Study 22436478 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 0
Study 19474823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 19474823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17209722 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey of Hope (JOH) education course
Number of subjects: 462
Study 17209722 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 462
Study 12630999 — intervention group
Group type: EXPERIMENTAL
Intervention: Precautionary positioning group (n = 59)
Number of subjects: 107
Study 12630999 — intervention group
Group type: COMPARATOR
Intervention: Non-precautionary positioning group (n = 48)
Number of subjects: 107
Study 10671339 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 117
Study 9328492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychosocial treatment
Number of subjects: 274
Study 9328492 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 274
Study 8473584 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment (CBT)
Number of subjects: 56
Study 8473584 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 56
Study 8473584 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 56
Study 3810052 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25
Study 3810052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31603013 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian lighting environment (intervention group)
Number of subjects: 54
Study 31603013 — intervention group
Group type: COMPARATOR
Intervention: Lighting as usual (control group)
Number of subjects: 54
Study 30203758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine in addition to conventional Anti-TB therapy and liver-protecting therapy
Number of subjects: 4200
Study 30203758 — intervention group
Group type: COMPARATOR
Intervention: Conventional Anti-TB therapy and liver-protecting therapy
Number of subjects: 4200
Study 27638993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 20
Study 27638993 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 20
Study 24809770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation (seawater)
Number of subjects: 61
Study 24809770 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroids (INS)
Number of subjects: 61
Study 24809770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (nasal saline irrigation + INS)
Number of subjects: 61
Study 22901955 — intervention group
Group type: EXPERIMENTAL
Intervention: STRETCH programme (educational outreach training of nurses to initiate and represcribe ART)
Number of subjects: 12282
Study 22901955 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 12282
Study 20536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of <150 mmHg
Number of subjects: 0
Study 20536619 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure target of <180 mmHg
Number of subjects: 0
Study 18412995 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and other antioxidants in foods (large doses)
Number of subjects: 0
Study 18412995 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fruit and vegetables
Number of subjects: 0
Study 15910137 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward associative strength (BAS)
Number of subjects: 0
Study 15910137 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward associative strength (FAS)
Number of subjects: 0
Study 12145999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg
Number of subjects: 4
Study 12145999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 50 mg
Number of subjects: 4
Study 12145999 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg (crossover study)
Number of subjects: 4
Study 10538330 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for estimating medical costs based on variables such as length of stay, nursing workload, severity of condition, and procedures recorded.
Number of subjects: 102
Study 10538330 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the cost model using a second sample of 29 patients.
Number of subjects: 102
Study 8679024 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 50 mg of 0.25% bupivacaine and 1 mg of morphine
Number of subjects: 30
Study 8679024 — intervention group
Group type: COMPARATOR
Intervention: Group II: 50 mg of 0.25% bupivacaine and 100 micrograms of fentanyl
Number of subjects: 30
Study 1827107 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg (2 x 125 mg capsules) 12-hourly
Number of subjects: 225
Study 1827107 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 250 mg (one capsule) 6-hourly
Number of subjects: 225
Study 7020820 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 200
Study 7020820 — intervention group
Group type: EXPERIMENTAL
Intervention: cephalexin
Number of subjects: 200
Study 7020820 — intervention group
Group type: EXPERIMENTAL
Intervention: carfecillin
Number of subjects: 200
Study 7020820 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 200
Study 7020820 — intervention group
Group type: EXPERIMENTAL
Intervention: all 3 antibiotics
Number of subjects: 200
Study 30677646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics-guided intervention arm (guided-care)
Number of subjects: 1167
Study 30677646 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1167
Study 30677646 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent medications after switching from incongruent medications
Number of subjects: 1167
Study 30677646 — intervention group
Group type: COMPARATOR
Intervention: Incongruent medications
Number of subjects: 1167
Study 28112981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral porcine placental extract (PPE) 300 mg/day
Number of subjects: 50
Study 28112981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25070148 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of Soli 6 mg plus TOCAS 0.4 mg
Number of subjects: 1066
Study 25070148 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of Soli 9 mg plus TOCAS 0.4 mg
Number of subjects: 1066
Study 25070148 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of Soli 6 mg plus TOCAS 0.4 mg or Soli 9 mg plus TOCAS 0.4 mg
Number of subjects: 1066
Study 23292744 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group (19 subjects)
Number of subjects: 40
Study 23292744 — intervention group
Group type: COMPARATOR
Intervention: Non-PCOS group (21 subjects)
Number of subjects: 40
Study 23292744 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging at 2 mm slice thickness
Number of subjects: 40
Study 20399146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of imipramine with pseudoephedrine
Number of subjects: 100
Study 20399146 — intervention group
Group type: COMPARATOR
Intervention: Imipramine with placebo
Number of subjects: 100
Study 19196111 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + LAS
Number of subjects: 30
Study 19196111 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study 19196111 — intervention group
Group type: COMPARATOR
Intervention: LAS alone
Number of subjects: 30
Study 17571256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg
Number of subjects: 308
Study 17571256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg
Number of subjects: 308
Study 17571256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g
Number of subjects: 308
Study 15669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 11
Study 15669707 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 11
Study 15669707 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 11
Study 12477522 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 30
Study 12477522 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LH
Number of subjects: 30
Study 9811984 — intervention group
Group type: EXPERIMENTAL
Intervention: OPLL patients
Number of subjects: 19
Study 9811984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 7633015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin 200 mg iv q12h
Number of subjects: 1
Study 7633015 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg tid (initially) then reduced to 200 mg tid after toxicity was observed
Number of subjects: 1
Study 7633015 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 400 mg bid (initially)
Number of subjects: 1
Study 2199211 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (2.5 mg.ml-1)
Number of subjects: 10
Study 2199211 — intervention group
Group type: COMPARATOR
Intervention: Methacholine (0.13-4.0 mg.ml-1)
Number of subjects: 10
Study 845912 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of simple ambulatory practice profiles
Number of subjects: 21
Study 845912 — intervention group
Group type: COMPARATOR
Intervention: No feedback of profiles (Control)
Number of subjects: 21
Study 31034594 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) and physical therapy (PT)
Number of subjects: 63
Study 31034594 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 28383379 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐balanced vaginal gel containing lactic acid
Number of subjects: 136
Study 28383379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactate‐free gel)
Number of subjects: 136
Study 26307181 — intervention group
Group type: EXPERIMENTAL
Intervention: Moleca(®) footwear (worn for at least 6h/day, 7 days/week, over 6 months)
Number of subjects: 56
Study 23768792 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 121
Study 23768792 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping
Number of subjects: 121
Study 21112360 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffet lunches (pizza/tacos/sub sandwiches with salad bar and choice of beverage and dessert)
Number of subjects: 32
Study 21112360 — intervention group
Group type: COMPARATOR
Intervention: Control lunch (ad libitum, fixed-item lunch)
Number of subjects: 32
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet restricted in fermentable, poorly absorbed carbohydrates (including fructose, fructans, sorbitol, and other sugar alcohols)
Number of subjects: 0
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of soluble fiber
Number of subjects: 0
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of peppermint oil
Number of subjects: 0
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber (general)
Number of subjects: 0
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (live-culture yogurt and buttermilk)
Number of subjects: 0
Study 19559137 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified exclusion diet and stepwise reintroduction of foods
Number of subjects: 0
Study 16751757 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled bipolar conjunctival cautery
Number of subjects: 144
Study 15134307 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with catch-up growth
Number of subjects: 60
Study 15134307 — intervention group
Group type: EXPERIMENTAL
Intervention: Children without catch-up growth
Number of subjects: 60
Study 15134307 — intervention group
Group type: EXPERIMENTAL
Intervention: Children followed longitudinally for 1 year
Number of subjects: 60
Study 15134307 — intervention group
Group type: COMPARATOR
Intervention: Socio-economic status
Number of subjects: 60
Study 11501507 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment (Silkis ointment)
Number of subjects: 0
Study 11501507 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 15 microg g(-1) ointment
Number of subjects: 0
Study 11501507 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0
Study 9375952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (12.5 mg or 25 mg once daily, titrated to 200 mg)
Number of subjects: 3200
Study 9375952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3200
Study 8352424 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed shed blood
Number of subjects: 26
Study 8352424 — intervention group
Group type: COMPARATOR
Intervention: Unwashed shed blood
Number of subjects: 26
Study 3112727 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 21
Study 3112727 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 21
Study 30015637 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute physical exertion protocol
Number of subjects: 87
Study 30015637 — intervention group
Group type: COMPARATOR
Intervention: at rest
Number of subjects: 87
Study 29298678 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 150
Study 29298678 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (exergaming)
Number of subjects: 150
Study 29298678 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 150
Study 27192969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670
Study 27192969 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib (other dose groups)
Number of subjects: 670
Study 27192969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (all doses)
Number of subjects: 670
Study 26715519 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block with 0.33% ropivacaine
Number of subjects: 60
Study 26715519 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 60
Study 24324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative corticosteroid administration (PCA group)
Number of subjects: 39
Study 24324377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 39
Study 20570883 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFR expression (assessed by immunohistochemistry) in 103 out of 145 OPLs (71%)
Number of subjects: 162
Study 20570883 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH-positive lesions (increased EGFR gene copy number) in 20 out of 49 OPLs (41%)
Number of subjects: 162
Study 20570883 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH-positive group
Number of subjects: 162
Study 18954355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel administered topically every 24 h for 6 consecutive days
Number of subjects: 35
Study 18954355 — intervention group
Group type: COMPARATOR
Intervention: 1.23% sodium fluoride gel administered topically every 24 h for 6 consecutive days
Number of subjects: 35
Study 16176154 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 Q-Gel Softsules
Number of subjects: 12
Study 16176154 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 all-Q
Number of subjects: 12
Study 16176154 — intervention group
Group type: COMPARATOR
Intervention: CoQ10 Q-SorB
Number of subjects: 12
Study 16176154 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 all-Q and Q-Gel
Number of subjects: 12
Study 12803737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg (increased to 60 mg if necessary)
Number of subjects: 155
Study 12803737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (increased to 10 mg if necessary)
Number of subjects: 155
Study 10795650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 200 microg
Number of subjects: 0
Study 10795650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 400 microg
Number of subjects: 0
Study 10795650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8969284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 49
Study 8969284 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 49
Study 1507019 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies evaluated based on actual clinical changes rather than presumed etiologic factors.
Number of subjects: 0
Study 1507019 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to correlate events observed at sites within the dentition.
Number of subjects: 0
Study 6484553 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 3 g
Number of subjects: 12
Study 6484553 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 12
Study 6484553 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 g and 0.5 g (6 h apart)
Number of subjects: 12
Study 30185793 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 8 mg
Number of subjects: 48
Study 30185793 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 16 mg
Number of subjects: 48
Study 30185793 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 8 mg + CBD 16 mg
Number of subjects: 48
Study 30185793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26948254 — intervention group
Group type: EXPERIMENTAL
Intervention: No GRV monitoring (n = 26)
Number of subjects: 51
Study 26948254 — intervention group
Group type: COMPARATOR
Intervention: GRV monitoring (n = 25)
Number of subjects: 51
Study 24597866 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695
Study 24597866 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study 22266974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 40
Study 22266974 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 40
Study 20617289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight loss (WL) group
Number of subjects: 71
Study 20617289 — intervention group
Group type: COMPARATOR
Intervention: Weight stable (WS) control group
Number of subjects: 71
Study 18945240 — intervention group
Group type: COMPARATOR
Intervention: IV morphine sulfate 0.1 mg/kg
Number of subjects: 328
Study 18945240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone 0.125 mg/kg
Number of subjects: 328
Study 15823446 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF) challenge
Number of subjects: 12
Study 15823446 — intervention group
Group type: COMPARATOR
Intervention: Lyso-PAF (L-PAF) challenge
Number of subjects: 12
Study 12544672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (32 mg daily)
Number of subjects: 80
Study 12544672 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 80
Study 10972216 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine stenting
Number of subjects: 280
Study 10972216 — intervention group
Group type: COMPARATOR
Intervention: No routine stenting
Number of subjects: 280
Study 8928537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program (4 sessions)
Number of subjects: 36
Study 8928537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 36
Study 1740930 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited intravenous fluids (1294 +/- 58 ml)
Number of subjects: 113
Study 1740930 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (500 ml or less, 485 +/- 2 ml)
Number of subjects: 113
Study 6408663 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day amitriptyline (AT)
Number of subjects: 74